Tonix to Present Programs for PTSD, Fibromyalgia Drug Candidate at European Conference

Tonix to Present Programs for PTSD, Fibromyalgia Drug Candidate at European Conference
0
(0)

Tonix Pharmaceuticals, a company dedicated to developing next-gen medicines for fibromyalgia and post-traumatic stress disorder (PTSD), announced its Executive Vice President of Commercial Planning and Development, Ronald Notvest, Ph.D., MBA, will present at the 10th Annual BIO Europe Spring Conference in Sweden.

Notvest’s presentation will provide a corporate update and a general overview of Tonix Pharmaceuticals’ fibromyalgia and PTSD clinical programs. Tonix is currently evaluating the drug candidate TNX-102 SL, an FDA Investigational New Drug, in:

According to a press release, the presentation will be at 4:45 p.m. Central European Time on Tuesday, April 5, at the Kistamässan Convention Center in Stockholm, Sweden.

Tonix Pharmaceuticals is working to develop next-generation medicines for common central nervous system disorders such as fibromyalgia and PTSD. These conditions still have inadequate treatment options for chronic disability and their recurrence rate poses an economic challenge to healthcare providers.

Fibromyalgia is one of the most common musculoskeletal conditions, often misdiagnosed and misunderstood. Patients frequently report suffering from symptoms such as muscle and joint pain, short pain threshold, and fatigue, which can lead to anxiety, depression, and social isolation.

PTSD is a psychological disorder that develops in certain people who have survived shocking, traumatic, or life-threatening events. People with PTSD generally have trouble differentiating from a stressful or dangerous situation and a non-threatening event, causing them to experience multiple symptoms associated with fight-or-flight responses.

PTSD symptoms include flashbacks, nightmares, anxiety, avoiding places that trigger memories of traumatic experiences, depression, memory loss, being easily startled or feeling tense, insomnia, and anger issues.

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.
×
Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.
Latest Posts
  • avoid being sedentary
  • resistance exercise and fibromyalgia
  • National Fibromyalgia Awareness Day
  • telehealth

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?